EPO and bronchopulmonary dysplasia: The 2011 EPICE study found that 13.9% of babies born 24–29 weeks received PNC for BPD, but rates varied from 3.1% (Portugal) to 49.4% (Germany).26 In a randomised controlled trial (RCT) of erythropoietin versus placebo involving 30 units in the USA, 38% of babies born 24 to 27+6 weeks who survived to discharge were treated with PNC.27 The median (IQR) postnatal age for dexamethasone initiation was very similar to our study 29 (20–44) days with a similar duration 10 (5–15) days, but use of prednisolone or methylprednisolone was earlier.